Titration schedule planner
GLP-1 Titration Schedule Planner
Generate a personalized week-by-week titration calendar for any GLP-1 medication using the exact dose-escalation schedule from each drug's FDA Prescribing Information. Select your medication, choose a start date, and optionally indicate your current dose to see only the remaining schedule.
Important: Your prescriber may adjust this schedule based on your tolerance. This is the standard FDA-label protocol — do not change doses without medical guidance. If side effects are intolerable at any step, contact your prescriber before the next increase.
Wegovy (semaglutide 2.4 mg) — titration calendar
| Week | Date range | Dose | Pen color | Notes |
|---|---|---|---|---|
| 1 | Apr 13, 2026 — Apr 19, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 2 | Apr 20, 2026 — Apr 26, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 3 | Apr 27, 2026 — May 3, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 4 | May 4, 2026 — May 10, 2026 | 0.25 mg weekly | Light blue | Starting dose — dose-escalation phase |
| 5 | May 11, 2026 — May 17, 2026 | 0.5 mg weekly | Red-violet | |
| 6 | May 18, 2026 — May 24, 2026 | 0.5 mg weekly | Red-violet | |
| 7 | May 25, 2026 — May 31, 2026 | 0.5 mg weekly | Red-violet | |
| 8 | Jun 1, 2026 — Jun 7, 2026 | 0.5 mg weekly | Red-violet | |
| 9 | Jun 8, 2026 — Jun 14, 2026 | 1 mg weekly | Yellow | |
| 10 | Jun 15, 2026 — Jun 21, 2026 | 1 mg weekly | Yellow | |
| 11 | Jun 22, 2026 — Jun 28, 2026 | 1 mg weekly | Yellow | |
| 12 | Jun 29, 2026 — Jul 5, 2026 | 1 mg weekly | Yellow | |
| 13 | Jul 6, 2026 — Jul 12, 2026 | 1.7 mg weekly | Teal | |
| 14 | Jul 13, 2026 — Jul 19, 2026 | 1.7 mg weekly | Teal | |
| 15 | Jul 20, 2026 — Jul 26, 2026 | 1.7 mg weekly | Teal | |
| 16 | Jul 27, 2026 — Aug 2, 2026 | 1.7 mg weekly | Teal | |
| 17 | Aug 3, 2026 — Aug 9, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
| 18 | Aug 10, 2026 — Aug 16, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
| 19 | Aug 17, 2026 — Aug 23, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
| 20 | Aug 24, 2026 — Aug 30, 2026 | 2.4 mg weekly | Dark blue | MAINTENANCEMaintenance dose reached |
How the planner works
Every dose, duration, and pen color in this planner comes directly from the FDA Prescribing Information (PI) for each medication. The planner does not invent or modify doses — it generates a calendar view of the exact FDA-label protocol.
- Wegovy (semaglutide) [1]: 16-week titration from 0.25 mg to 2.4 mg maintenance, in 4-week steps.
- Ozempic (semaglutide) [2]: 4-week start at 0.25 mg, then 0.5 mg, with optional increases to 1.0 mg and 2.0 mg.
- Zepbound / Mounjaro (tirzepatide) [3][4]: 16-week titration from 2.5 mg to 15 mg maximum, increasing by 2.5 mg every 4 weeks.
- Foundayo (orforglipron) [5]: Daily oral tablet. 12-week titration from 3 mg to 36 mg maintenance.
Important warning
Your prescriber may adjust this schedule based on your tolerance. This is the standard FDA-label protocol. Do not change doses without medical guidance. If you are experiencing intolerable side effects at any dose level, contact your prescriber before your next scheduled increase — they may recommend staying at the current dose for additional weeks or reducing the dose.
What this planner does NOT do
- It does not provide medical advice or replace a conversation with your prescriber.
- It does not account for individual tolerance — the FDA labels include “as tolerated” language that your prescriber will apply to your situation.
- It does not generate prescriptions or medication orders.
- It does not track actual injection/pill dates — it shows the planned schedule for reference.
Important disclaimer
This planner is for educational purposes only and does not constitute medical advice or a prescription. The titration schedules shown are the standard FDA-label protocols. Your actual titration may differ based on your clinical response, tolerance, and your prescriber's judgment. Never adjust your medication dose without consulting your prescriber.
Related tools and research
- GLP-1 Dose Plotter — visualize your dose history over time
- GLP-1 Unit Converter — convert between mg, mL, and units
- GLP-1 Missed Dose Guide — what to do if you miss a dose during titration
- GLP-1 Weight Loss Calculator — week-by-week weight loss projections
- Switching between GLP-1 medications — what happens to titration when you switch drugs
- Semaglutide side effects: what to expect — the GI side effects that may affect titration pace
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1: Recommended Dosage. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
- 2.Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s020lbl.pdf
- 3.Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
- 4.Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866Orig1s000lbl.pdf
- 5.Eli Lilly and Company. Foundayo (orforglipron) tablets — Prescribing Information. FDA / Drugs@FDA. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218226s000lbl.pdf